Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer

NCT00924066 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00924066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00924066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2008
Completion date
December 31, 2013
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical carcinoma, cervical carcinoma, non-squamoustype